lurasidone

Catalog No.S5714 Batch:S571401

Print

Technical Data

Formula

C28H36N4O2S

Molecular Weight 492.68 CAS No. 367514-87-2
Solubility (25°C)* In vitro DMSO 7 mg/mL (14.2 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Lurasidone (SM-13496) is a second-generation antipsychotic agent that exhibits full antagonism at dopamine D2 and serotonin 5-HT2A receptors with binding affinities Ki = 1 nM and Ki = 0.5 nM, respectively. It also has high affinity for serotonin 5-HT7 receptors (Ki = 0.5 nM), partial agonist activity at 5-HT1A receptors (Ki = 6.4 nM) and lacks affinity for histamine H1 and muscarinic M1 receptors.
Targets
5-HT2A [1]
(Cell-free assay)
5-HT7 receptor [1]
(Cell-free assay)
D2 receptor [1]
(Cell-free assay)
5-HT1A receptor [1]
(Cell-free assay)
0.5 nM(Ki) 0.5 nM(Ki) 1 nM(Ki) 6.4 nM(Ki)
In vitro Lurasidone is a new atypical antipsychotic in the benzoisothiazoles class of chemicals. Like most second-generation antipsychotics it is a full antagonist at dopamine D2 and serotonin 5-HT2A receptors, and is a partial agonist at 5-HT1A receptors. It has much greater affinity for 5-HT7 subtype receptors than other atypical antipsychotics. Lurasidone also has high affinity for the 5-HT1A subtype, α2c-adrenergic receptors and low affinity for α1-adrenergic receptors. It has minimal affinity for 5-HT2C receptors and negligible affinity for histamine H1 and muscarinic receptors[2].
In vivo Lurasidone is rapidly absorbed, reaching peak concentrations within 1.5–3 hours (tmax) after single and multiple oral doses. Once absorbed, it extensively distributes in tissues and rapidly enters the CNS. Lurasidone has high binding to human plasma albumin and alpha-1-glycoprotein (≥99%)[2]. Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse. The elimination half-life of lurasidone is about 20-40 h. Mean Cmax and area under the curve (AUC) for lurasidone were approximately threefold and twofold greater, respectively, in a comparison of administration with food v. fasting. Lurasidone absorption is independent of food fat content. Lurasidone is metabolised primarily via CYP3A4[1]. In animal studies, lurasidone penetrated the placental barrier and distributed into the fetus, and was excreted in milk during lactation[2].

Protocol (from reference)

Selleck's lurasidone has been cited by 2 publications

Amisulpride as a potential disease-modifying drug in the treatment of tauopathies [ Alzheimers Dement, 2023, 10.1002/alz.13090] PubMed: 37218673
A review on computer-aided chemogenomics and drug repositioning for rational COVID-19 drug discovery [ Chem Biol Drug Des, 2022, 100(5):699-721] PubMed: 36002440

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.